Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 2;4:14. doi: 10.1038/s41746-021-00381-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a High tumor mutation burden (TMB) is associated with beneficial post-IO outcomes, as observed in the overall IO cohort (log-rank P-value of 6 × 10⁻⁴, median survival of 13.3 vs. 24.3 months for TMB non-high vs. high groups, respectively). b DeePaN can identify patients with non-high TMB but with beneficial post-IO outcomes. Subgroups discovered by “DeePaN” are able to strategy TMB-non-high patients into subgroups with significantly differentiated survival post IO therapy (P-value of 3.8 × 10⁻⁶ from log-rank test, median survival of 20.8 months and 10.8 months, respectively), with about 10 months’ median survival difference between the IO-beneficial vs. non-beneficial group.